Connection

CHAD CREIGHTON to TOR Serine-Threonine Kinases

This is a "connection" page, showing publications CHAD CREIGHTON has written about TOR Serine-Threonine Kinases.
Connection Strength

1.236
  1. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell. 2017 06 12; 31(6):820-832.e3.
    View in: PubMed
    Score: 0.442
  2. MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling. J Clin Invest. 2019 03 01; 129(3):1015-1029.
    View in: PubMed
    Score: 0.124
  3. Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene. 2017 03; 36(10):1384-1393.
    View in: PubMed
    Score: 0.106
  4. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016 Mar 15; 14(10):2476-89.
    View in: PubMed
    Score: 0.102
  5. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Mar 20; 507(7492):315-22.
    View in: PubMed
    Score: 0.088
  6. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2013 Apr; 138(2):369-81.
    View in: PubMed
    Score: 0.082
  7. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res. 2012 Sep 01; 18(17):4633-45.
    View in: PubMed
    Score: 0.079
  8. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
    View in: PubMed
    Score: 0.059
  9. A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene. 2007 Jul 12; 26(32):4648-55.
    View in: PubMed
    Score: 0.054
  10. MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. Nat Commun. 2022 01 11; 13(1):245.
    View in: PubMed
    Score: 0.038
  11. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014 Dec; 46(12):1267-73.
    View in: PubMed
    Score: 0.023
  12. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
    View in: PubMed
    Score: 0.023
  13. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010 Feb; 24(2):447-63.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.